Chrono is combining a biologically timed transdermal drug delivery system with a behavorial support delivered via an app to help people manage hard-to-treat conditions. Their first application is smoking cessation.
Using a proprietary collagen-based technology, Innocoll is successfully distributing products that treat post-operative pain, heal diabetic foot infections, and prevent post-surgical adhesions. Innocoll is listed on the NASDAQ as INNL.
Using neuromodulation treatments, Neuromod is helping people with chronic and often debilitating tinnitus, informally called "ringing in the ears."
Inflammasomes generate signals that cause immune cells to fight infections. Inflazome is developing novel treatments for inflammation-related diseases by precisely blocking unwanted inflammasome signals.
Developing a unique portfolio of neurokinin (NK) receptor antagonists, NeRRe Therapeutics is aiming to treat common debilitating respiratory and women's health conditions caused by neuronal hypersensitivity.
Velicept is developing best-in-class compounds with the potential to fill unmet medical needs. Its lead program, solabegron, is a highly differentiated novel compound being investigated for overactive bladder (OAB) and irritable bowel syndrome (IBS).
Fund 1 Companies
With extensive experience in lipid science, Amarin is developing novel therapeutics for the treatment of cardiovascular disorders. Fountain has exited this investment.
Before being acquired by Acorda Therapeutics for $525M in cash in October 2014, Civitas was applying its dry powder inhalation drug delivery technology to Parkinson’s treatments. Fountain has exited this investment.
Genable developed a gene therapy platform to suppress and replace genes associated with Retinitis Pigmentosa. The company was acquired by Spark Therapeutics in March 2016. Fountain has exited this investment.
With a portfolio of unique interventional neurovascular devices, Neuravi is improving clinical outcomes for stroke patients. Johnson & Johnson acquired the company in March 2017. Fountain has exited this investment.
Following a successful IPO, Mainstay Medical (MSTY) is bringing to market an implantable neurostimulation system for people with disabling Chronic Low Back Pain (CLBP).
Targeting the human immune system, Opsona is developing drugs with wide applicability to conditions such as autoimmune and inflammatory diseases, solid organ transplantation and oncology.
Aiming to help people undergoing vascular surgery, Vivasure Medical has developed a bioabsorbable technology delivered percutaneously to assist in vessel closure.
Cappella built and distributed a bifurcation stent to protect coronary sidebranch arteries during cardiac procedures. Now called ArraVasc Limited, they are focused on peripheral vascular products. This investment is inactive.
Leveraging oral small molecules, Trino Therapeutics was focused on treating and managing inflammatory indications such as inflammatory bowel disease (IBD). The company ceased operations in 2017 and this investment is inactive.
With an implantable infusion pump, Palyon Medical was treating chronic pain, spasticity and diseases of the central nervous system. The company ceased operations in 2015 and this investment is inactive.
We want to hear from you
If you are an entrepreneur with an ambitious plan, use the button below to say hello.